Stay updated on Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial

Sign up to get notified when there's something new on the Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.3%
    Check dated 2025-02-03T05:30:02.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.3%
    Check dated 2025-01-19T19:43:08.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The website has updated the intervention type information to reflect a verified status by the PETHEMA Foundation as of September 2022, while also noting a revision from v2.13.3 to v2.14.0.
    Difference
    3%
    Check dated 2025-01-12T16:54:05.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    The website has been updated from version v2.13.2 to v2.13.3.
    Difference
    0.3%
    Check dated 2024-12-14T12:15:23.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The website has been updated from version 2.12.2 to 2.13.2, indicating a new release with potential improvements or features.
    Difference
    0.3%
    Check dated 2024-12-07T10:18:05.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    The website has removed a detailed section regarding data download options and fields related to clinical study information.
    Difference
    13%
    Check dated 2024-11-23T03:54:22.000Z thumbnail image

Stay in the know with updates to Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial page.